PDEX Quote, Financials, Valuation and Earnings

VolitionRX has a net margin of 12.15% compared to Pro-Dex's net margin of -1226.82%. Pro-Dex's return on equity of 21.59% beat VolitionRX's return on equity of --.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 10.45%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 491.71%. Given that VolitionRX has higher upside potential than Pro-Dex, analysts believe VolitionRX is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are larger than VolitionRX quarterly revenues of $474.5K. Pro-Dex's net income of $2M is higher than VolitionRX's net income of -$5.8M. Notably, Pro-Dex's price-to-earnings ratio is 24.45x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.73x versus 36.80x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 12.15% compared to Pro-Dex's net margin of -4291.67%. Pro-Dex's return on equity of 21.59% beat Catheter Precision's return on equity of -65.84%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 10.45%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 387.69%. Given that Catheter Precision has higher upside potential than Pro-Dex, analysts believe Catheter Precision is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are larger than Catheter Precision quarterly revenues of $96K. Pro-Dex's net income of $2M is higher than Catheter Precision's net income of -$4.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.45x while Catheter Precision's PE ratio is 0.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.73x versus 1.09x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 12.15% compared to Pro-Dex's net margin of 17.38%. Pro-Dex's return on equity of 21.59% beat West Pharmaceutical Services's return on equity of 18.15%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 10.45%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 24.34%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Pro-Dex pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pro-Dex quarterly revenues are $16.8M, which are smaller than West Pharmaceutical Services quarterly revenues of $748.8M. Pro-Dex's net income of $2M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.45x while West Pharmaceutical Services's PE ratio is 34.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.73x versus 5.86x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 12.15% compared to Pro-Dex's net margin of -10.04%. Pro-Dex's return on equity of 21.59% beat Xtant Medical Holdings's return on equity of -35.34%.

Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 10.45%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Xtant Medical Holdings has higher upside potential than Pro-Dex, analysts believe Xtant Medical Holdings is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Pro-Dex's net income of $2M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Pro-Dex's price-to-earnings ratio is 24.45x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.73x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.